GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
38.17
+0.02 (+0.05%)
At close: 4:02PM EST

38.17 0.00 (0.00%)
After hours: 4:02PM EST

Stock chart is not supported by your current browser
Previous Close38.15
Open37.98
Bid37.80 x 100
Ask38.17 x 700
Day's Range37.98 - 38.18
52 Week Range34.52 - 44.54
Volume4,316,170
Avg. Volume5,732,661
Market Cap86.511B
Beta0.84
PE Ratio (TTM)29.27
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.01 (5.31%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?
    Zacks8 hours ago

    J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

    Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

  • SmarterAnalystyesterday

    Here’s Why Neurometrix Inc Rose as Much as 60% Today

    Shares of Neurometrix Inc (NASDAQ:NURO) rocketed more than 60% higher at one point Wednesday morning after the healthcare company announced a new collaboration with GlaxoSmithKline plc (ADR) (NYSE:GSK), involving Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Specifically, GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. Neurometrix will receive a payment of $5 million for the assets relating to Quell technology for markets outside the U.S and up to $21.5 million, upon the achievement of certain development and commercialization milestones. Investors will need to wait to see more precise details, but for a penny stock such as Neurometrix, this is pretty amazing no matter the exact dollar amount.

  • Reutersyesterday

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline (GSK.L) is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region. Five years ago, forecasters predicted annual African drug sales would reach $45 billion by 2020.

  • Reutersyesterday

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region.

  • MarketWatchyesterday

    NeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell

    Shares of NeuroMetrix Inc. rocketed 78% toward a 7-month high in active premarket trade Wednesday, after chronic pain treatments company announced a collaboration with GlaxoSmithLine PLC involving NeuroMetrix's ...

  • Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa
    Bloombergyesterday

    Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa

    GlaxoSmithKline Plc is cutting jobs in Africa and restructuring in more than two dozen countries across the continent, reversing earlier expansion efforts as new Chief Executive Emma Walmsley tries to ...

  • What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?
    Simply Wall St.2 days ago

    What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as GlaxoSmithKline plc (LSE:GSK) a safer option. Market participants who are conscious of risk tend toRead More...

  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist3 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
    Zacks3 days ago

    Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

    Glaxo's (GSK) influenza vaccine ??? Fluarix Quadrivalent receives FDA approval for label expansion.

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist6 days ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • A Look at Insys Therapeutics’ Financial Performance
    Market Realist6 days ago

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.

  • What Analysts Recommend for Insys Therapeutics and Peers
    Market Realist6 days ago

    What Analysts Recommend for Insys Therapeutics and Peers

    What to Expect from Insys Therapeutics in 2018Company overview

  • Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
    Zacks6 days ago

    Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

    Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

  • AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
    Zacks7 days ago

    AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

    AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

  • Teva Stock Has Risen Significantly since November Lows: What’s Next?
    Market Realist8 days ago

    Teva Stock Has Risen Significantly since November Lows: What’s Next?

    Teva Pharmaceuticals released its 3Q17 earnings results on November 2, 2017. The disappointing earnings and the company’s lowering of its fiscal 2017 guidance triggered negative investor sentiments, which led to a massive decline of approximately 20% in TEVA stock prices. The company has run into troubles over the past year and it reported a dismal performance in 3Q17. For details, read, Inside Teva’s 3Q17 Performance.

  • Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
    Zacks8 days ago

    Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

    Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.

  • Key Risks Facing Mylan in January 2018
    Market Realist8 days ago

    Key Risks Facing Mylan in January 2018

    Mylan: An In-Depth Look

  • Emergent Down on '18 View, Posts Preliminary '17 Results
    Zacks9 days ago

    Emergent Down on '18 View, Posts Preliminary '17 Results

    Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.

  • Reuters9 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Reuters9 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In
    Bloomberg9 days ago

    Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In

    CEO Walmsley has reshuffled 40 percent of top managers to spark innovation

  • What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?
    Simply Wall St.9 days ago

    What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?

    GlaxoSmithKline plc’s (LSE:GSK) latest earnings update in September 2017 confirmed that the company faced a immense headwind with earnings falling by -89.17%. Below, I’ve laid out key growth figures onRead More...

  • The Wall Street Journal10 days ago

    Rivals Help Fund Regeneron’s Gene-Sequencing Effort

    Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.

  • Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth
    Bloomberg10 days ago

    Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth

    GlaxoSmithKline Plc’s new chief executive officer, Emma Walmsley, has revamped the top ranks of the U.K.’s largest drugmaker, replacing about 50 of the top 125 managers since taking over last year.

  • GSK's Redfern Says Pharma Remains Number One Priority
    Bloomberg Video10 days ago

    GSK's Redfern Says Pharma Remains Number One Priority

    Jan.08 -- GSK Chief Strategy Officer David Redfern discusses investment in research and development and M&A in the healthcare industry. He speaks with Erik Schatzker on "Bloomberg Daybreak: Asia" from the JPMorgan Healthcare Conference.